Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

COSTA MESA, CA -- (Marketwired) -- 05/09/17 -- (OTCQB: NMUS) announced that an additional United States…

Continue Reading

Nemus Bioscience Announces $20 Million Series E Preferred Stock Financing

COSTA MESA, CA — (Marketwired) — 05/04/17 — NEMUS Bioscience, Inc. (OTCQB: NMUS) (the “Company”) today…

Continue Reading

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

COSTA MESA, CA -- (Marketwired) -- 03/22/17 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company--s…

Continue Reading

Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

COSTA MESA, CA — (Marketwired) — 03/20/17 — (OTCQB: NMUS) announced that the company has signed…

Continue Reading

NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development

COSTA MESA, CA -- (Marketwired) -- 03/03/17 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that…

Continue Reading